VJNeurology is committed to improving our service to you

Share this video  

VJNeurology is committed to improving our service to you

ECTRIMS 2021 | How does ublituximab compare to other anti-CD20 mAbs?

Lawrence Steinman, MD, Stanford University, Stanford, CA, discusses how ublituximab, an investigation anti-CD20 monoclonal antibody for the treatment of relapsing multiple sclerosis (MS), compares to currently available CD20-targeting agents. Ocrelizumab and rituximab are approved anti-CD20 monoclonal antibodies (mAbs) and are widely used for the treatment of relapsing-remitting MS. No direct comparisons have been made in head-to-head trials, but Dr Steinman believes the evidence gathered in Phase III trials for ublituximab is promising. If approved, real-world data on the use of ublituximab will tell us more about how the agents compare to each other. This interview took place at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) congress 2021.

Disclosures

Dr Steinman consults for TGTx.